Supplement Focus on cardiometabolic matters – 2020 November 2020 Full text: PDF Peer Reviewed Contents Foreword from the Supplement Editors Gemma Figtree, Louise Burrell Cardiovascular medicine Dyslipidaemia in type 2 diabetes: cardiovascular risk assessment and management Nick S.R. Lan, Kharis Burns, Damon A. Bell, Gerald F. Watts Endocrinology and metabolism Nonalcoholic fatty liver disease Ross Apostolov, Josephine A. Grace Cardiometabolism clinic Reducing cardiovascular risk in type 2 diabetes: emerging therapies John Amerena Cardiometabolism clinic Aspirin therapy in diabetes: evidence and current recommendations Naomi Szwarcbard, Sophia Zoungas Cardiovascular medicine Diabetic kidney disease and CVD Jakob Appel Østergaard, Mark E. Cooper Advertisement Advertisement Advertisement
Cardiovascular medicine Dyslipidaemia in type 2 diabetes: cardiovascular risk assessment and management Nick S.R. Lan, Kharis Burns, Damon A. Bell, Gerald F. Watts
Cardiometabolism clinic Reducing cardiovascular risk in type 2 diabetes: emerging therapies John Amerena
Cardiometabolism clinic Aspirin therapy in diabetes: evidence and current recommendations Naomi Szwarcbard, Sophia Zoungas
